The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AbbVie Inc., Alimera Sciences Inc., Allergan Plc, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Clearside Biomedical, Enzo Biochem Inc., EyePoint Pharmaceuticals Inc., Kiora Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Viatris Inc., Aldeyra Therapeutics Inc., American Academy of Ophthalmology, L V PRASAD EYE INSTITUTE, Melinta Therapeutics LLC, and Prometheus Laboratories Inc. are some of the major market participants.
Although the increasing healthcare spending worldwide, development of novel drugs and treatments, rising cases of anterior uveitis will offer immense growth opportunities, the high cost of healthcare, side effects associated with usage of anterior uveitis medicines, and stringent government regulations will challenge the growth of the market participants.
To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Anterior Uveitis Treatment Market 2022-2026: Segmentation
Anterior Uveitis Treatment Market is segmented as below:
- Type
- Geography
- North America
- Asia
- Europe
- Rest Of World (ROW)
Learn more about the additional trends impacting the future of the market and the
positive and negative consequences on the businesses., download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR72239
Anterior Uveitis Treatment Market 2022-2026: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our anterior uveitis treatment market report covers the following areas:
This study identifies the increasing geriatric population as one of the prime reasons driving the anterior uveitis treatment market growth during the next few years.
Anterior Uveitis Treatment Market 2022-2026: Vendor Analysis
The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market.
We provide a detailed analysis of around 25 vendors operating in the Anterior Uveitis Treatment Market, including some of the vendors such as AbbVie Inc., Alimera Sciences Inc., Allergan Plc, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Clearside Biomedical, Enzo Biochem Inc., EyePoint Pharmaceuticals Inc., Kiora Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Viatris Inc., Aldeyra Therapeutics Inc., American Academy of Ophthalmology, among others.
Find additional highlights on the growth strategies adopted by vendors and their product offerings, Read Free Sample Report.
Anterior Uveitis Treatment Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist anterior uveitis treatment market growth during the next five years
- Estimation of the anterior uveitis treatment market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the anterior uveitis treatment market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of anterior uveitis treatment market vendors
We offer USD 1,000 worth of FREE customization at the time of purchase. Speak to our Analyst now!
Related Reports:
Multiple Sclerosis Market in the US by Type and Route of Administration- Forecast and Analysis 2022-2026
New Drug Delivery Systems Market by Route of Administration and Geography - Forecast and Analysis 2022-2026
Anterior Uveitis Treatment Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.09% |
Market growth 2022-2026 |
$ 145.89 million |
Market structure |
Fragmented |
YoY growth (%) |
3.52 |
Regional analysis |
North America, Asia, Europe, and Rest of World (ROW) |
Performing market contribution |
North America at 32% |
Key consumer countries |
US, Canada, Germany, China, and India |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
AbbVie Inc., Alimera Sciences Inc., Allergan Plc, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Clearside Biomedical, Enzo Biochem Inc., EyePoint Pharmaceuticals Inc., Kiora Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Viatris Inc., Aldeyra Therapeutics Inc., American Academy of Ophthalmology, L V PRASAD EYE INSTITUTE, Melinta Therapeutics LLC, and Prometheus Laboratories Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table Of Contents :
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Medications - Market size and forecast 2021-2026
- Exhibit 28: Chart on Medications - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Medications - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Medications - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Medications - Year-over-year growth 2021-2026 (%)
- 5.4 Surgery - Market size and forecast 2021-2026
- Exhibit 32: Chart on Surgery - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Surgery - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Surgery - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Surgery - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Asia - Market size and forecast 2021-2026
- Exhibit 46: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.5 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Canada - Market size and forecast 2021-2026
- Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.9 China - Market size and forecast 2021-2026
- Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.10 India - Market size and forecast 2021-2026
- Exhibit 70: Chart on India - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on India - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on India - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on India - Year-over-year growth 2021-2026 (%)
- 7.11 Germany - Market size and forecast 2021-2026
- Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 AbbVie Inc.
- Exhibit 85: AbbVie Inc. - Overview
- Exhibit 86: AbbVie Inc. - Business segments
- Exhibit 87: AbbVie Inc. - Key offerings
- Exhibit 88: AbbVie Inc. - Segment focus
- 10.4 Alimera Sciences Inc.
- Exhibit 89: Alimera Sciences Inc. - Overview
- Exhibit 90: Alimera Sciences Inc. - Product / Service
- Exhibit 91: Alimera Sciences Inc. - Key offerings
- 10.5 Bausch Health Companies Inc.
- Exhibit 92: Bausch Health Companies Inc. - Overview
- Exhibit 93: Bausch Health Companies Inc. - Business segments
- Exhibit 94: Bausch Health Companies Inc. - Key news
- Exhibit 95: Bausch Health Companies Inc. - Key offerings
- Exhibit 96: Bausch Health Companies Inc. - Segment focus
- 10.6 Clearside Biomedical
- Exhibit 97: Clearside Biomedical - Overview
- Exhibit 98: Clearside Biomedical - Key news
- Exhibit 99: Clearside Biomedical - Key offerings
- 10.7 Enzo Biochem Inc.
- Exhibit 100: Enzo Biochem Inc. - Overview
- Exhibit 101: Enzo Biochem Inc. - Key offerings
- 10.8 EyePoint Pharmaceuticals Inc.
- Exhibit 102: EyePoint Pharmaceuticals Inc. - Overview
- Exhibit 103: EyePoint Pharmaceuticals Inc. - Product / Service
- Exhibit 104: EyePoint Pharmaceuticals Inc. - Key offerings
- 10.9 Kiora Pharmaceuticals, Inc.
- Exhibit 105: Kiora Pharmaceuticals, Inc. - Overview
- Exhibit 106: Kiora Pharmaceuticals, Inc. - Product / Service
- Exhibit 107: Kiora Pharmaceuticals, Inc. - Key offerings
- 10.10 Novartis AG
- Exhibit 108: Novartis AG - Overview
- Exhibit 109: Novartis AG - Business segments
- Exhibit 110: Novartis AG - Key offerings
- Exhibit 111: Novartis AG - Segment focus
- 10.11 Pfizer Inc.
- Exhibit 112: Pfizer Inc. - Overview
- Exhibit 113: Pfizer Inc. - Business segments
- Exhibit 114: Pfizer Inc. - Key news
- Exhibit 115: Pfizer Inc. - Key offerings
- Exhibit 116: Pfizer Inc. - Segment focus
- 10.12 Santen Pharmaceutical Co. Ltd.
- Exhibit 117: Santen Pharmaceutical Co. Ltd. - Overview
- Exhibit 118: Santen Pharmaceutical Co. Ltd. - Business segments
- Exhibit 119: Santen Pharmaceutical Co. Ltd. - Key offerings
- Exhibit 120: Santen Pharmaceutical Co. Ltd. - Segment focus
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 121: Inclusions checklist
- Exhibit 122: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 123: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 124: Research methodology
- Exhibit 125: Validation techniques employed for market sizing
- Exhibit 126: Information sources
- 11.5 List of abbreviations
- Exhibit 127: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article